A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions.
Ido D. Weiss,Hadas Shoham,Ori Wald,Hanna Wald,Katia Beider,Michal Abraham,Neta Barashi,Eithan Galun,Arnon Nagler,Amnon Peled +9 more
TL;DR: Under physiological conditions, the bone marrow, spleen, blood and liver of Ccr5, but not of CCr1-deficient mice, contain reduced numbers of NK cells, suggesting a role for CCr5 in NK cell proliferation and circulation under physiological conditions and a complex role in determining the fate ofNK cells under pathological conditions.
Journal ArticleDOI
The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris
Alon Barsheshet,Hanoch Hod,Michael Shechter,Orna Sharabani-Yosef,Eti Rosenthal,Israel M. Barbash,Shlomi Matetzky,Reshef Tal,A.G. Bentancur,Ben Ami Sela,Arnon Nagler,Jonathan Leor,Jonathan Leor +12 more
TL;DR: The present pilot study shows, for the first time, that ECPT is associated with increased number and colony-forming capacity of circulating EPCs.
Journal ArticleDOI
A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.
Hagop M. Kantarjian,Jorge E. Cortes,Philipp le Coutre,Arnon Nagler,Javier Pinilla,Andreas Hochhaus,Dan Jones,Adam R. Craig,Eileen Carroll,Oliver G. Ottmann +9 more
TL;DR: In this phase I dose finding study, patients with imatinib-resistant or -intolerant Philadelphia (Ph+) chromosome-positive leukemias were eligible for treatment with INNO-406 orally at doses ranging from 30 mg once daily (qd) through 480 mg twice daily (bid).
Journal ArticleDOI
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.
Roni Shouval,Roni Shouval,Adi Eshel,Bar Dubovski,Amir A. Kuperman,Ivetta Danylesko,Joshua A Fein,Joshua A Fein,Shalev Fried,Mika Geva,Elizaveta Kouniavski,Hadar Neuman,Ayelet Armon-Omer,Radi Shahien,Efrat Muller,Cecilia Noecker,Elhanan Borenstein,Elhanan Borenstein,Yoram Louzoun,Arnon Nagler,Omry Koren +20 more
TL;DR: It is suggested that salivary microbial composition and metabolites are associated with the development of OM, offering new insights on pathophysiology and potential avenues of intervention.
Journal ArticleDOI
Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells
Gal Markel,Gal Markel,Rachel Seidman,Michal J. Besser,Naama Zabari,Rona Ortenberg,Ronnie Shapira,Avraham J. Treves,Ron Loewenthal,Arie Orenstein,Arnon Nagler,Jacob Schachter +11 more
TL;DR: It is shown that an NKLR-mediated killing directly correlates with the NKLR expression intensity on NK cells, and that common NKLR recognition patterns of tumors would allow implementation of this approach in solid malignancies and potentially in hematological malignancy, either independently or in adjunction to other modalities.